Product overview

Product overview

The content of this evidence summary was up to date in February 2022. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information.

Oritavancin (Tenkasi, Menarini) is a glycopeptide antibiotic given intravenously as a single dose. It has a marketing authorisation for treating acute bacterial skin and skin structure infections (ABSSSI) in adults.